These findings indicate a pronounced allodynia response
alone, an estimated 11.3% of the population, equivalent to around 38.4 million individuals, are affected by DM, primarily Type 2 diabetes
Other GLP-1 Medications: Liraglutide, Dulaglutide, and Exenatide Beyond semaglutide and tirzepatide, the GLP-1 drug class includes several other options with different pharmacokinetic profiles and dosing schedules
For emerging brands, this signals a product development opportunity
Learn As a patient- and science-driven company, we actively seek to expand our knowledge through advisory boards, market research and community engagement
A narrative review of approved and emerging anti-obesity medications